SCHEMBL24348036

SCHEMBL24348036

Cc1nc(CNC(=O)N(C)C)sc1-c1csc(-c2cc(F)c(O)c(F)c2F)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BPGM P07738 5/20 0.61
▸ PIK3CA P42336 2/20 0.37
▸ PIK3CD O00329 1/20 0.37
▸ OPRM1 P35372 2/20 0.33
▸ PIK3CG P48736 3/20 0.32
▸ MAPT P10636 2/20 0.32
▸ NPSR1 Q6W5P4 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ PI4KB Q9UBF8 3/20 0.31
▸ PIK3CB P42338 1/20 0.31
▸ PDPK1 O15530 1/20 0.31
▸ CLEC4M Q9H2X3 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24348501 0.90 BPGM (0.63) BPGMPIK3CAPIK3CDPIK3CGMAPT
SCHEMBL24348548 0.89 BPGM (0.77) BPGMPIK3CAPIK3CDOPRM1PIK3CG
SCHEMBL24348037 0.88 BPGM (0.60) BPGMPIK3CAPIK3CDPIK3CGMAPT
SCHEMBL24348465 0.85 BPGM (0.47) BPGMOPRM1HPGDPDPK1
SCHEMBL24272105 0.83 BPGM (0.51) BPGMPIK3CAPIK3CDOPRM1MAPT
SCHEMBL24349250 0.83 BPGM (0.55) BPGMPIK3CAPIK3CDPIK3CGMAPT
SCHEMBL24348035 0.83 BPGM (0.55) BPGMPIK3CAPIK3CDPIK3CGMEN1
SCHEMBL24348057 0.83 BPGM (0.69) BPGMPIK3CAPIK3CDOPRM1MAPT
SCHEMBL24348039 0.82 BPGM (0.71) BPGMPIK3CAPIK3CDOPRM1PIK3CG
SCHEMBL24349242 0.82 BPGM (0.73) BPGMPIK3CAPIK3CDOPRM1PIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 — — US disclosed
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 — — US disclosed
WO-2022056449-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION (US) 2022-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE BPGM, PGAM1, HBG1 BPGM 1/4885PIK3CA 568/4885PIK3CD 1201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback